150 North Wacker Drive
Suite 2360
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax

2024 Printed Publications Early Bird Sale on Now through September 29, 2023!

User Information

Create New Account

Lost Password


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule


Physician Fee Schedule


OPPS Fee Schedule


ASC Fee Schedule


APC Codes


DRG Codes


ASP Drug Pricing Files

July 2023
April 2023

CMS Transmittals

Important Notice: Change of Address

CodeMap® LCD-L39060


Printer Friendly Version

LCD for Platelet Rich Plasma Injections for Non-Wound Injections (L39060)
See related Articles:
A58790-Billing and Coding: Platelet Rich Plasma Injections for Non-Wound Injections
A58967-Response to Comments: Platelet Rich Plasma Injections for Non-Wound Injections

Contractor Information

Contractor Name: Noridian Healthcare Solutions, LLC - Full list of policies of this Medicare Contractor

Contractor Number: 03401

Contractor Type: MAC A

LCD Information

LCD ID Number: L39060 Status: A-Approved

LCD Title: Platelet Rich Plasma Injections for Non-Wound Injections

Geographic Jurisdiction: South Dakota Other Jurisdictions

Original Determination Effective Date: 01/23/2022

Original Determination Ending Date:

Revision Effective Date: 01/23/2022

Revision End Date:

CMS National Coverage Policy:

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, §1862(a)(1)(D) addresses services that are determined to be investigational or experimental.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 16, §10 General Exclusions from Coverage

CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, §270.3 Blood-Derived Products for Chronic Non-healing Wounds.1 Effective August 2, 2012, updated 4/13/21, the Centers for Medicare and Medicaid Services (CMS) has determined that platelet-rich plasma (PRP) – an autologous blood-derived product, will be covered for the treatment of chronic non-healing diabetic wounds under section 1862(a)(1)(A) for a duration of 20 weeks, when prepared by devices who FDA cleared. Indications include the management of exuding cutaneous wounds, such as diabetic ulcers.

CMS Internet-Only Manual, Pub. 100-04, Medicare Claims Processing Manual, Chapter 23, §30A Physician’s Services

CMS Internet-Only Manual, Pub. 100-04, Medicare Claims Processing Manual, Chapter 30, §50.3.1 Mandatory ABN Uses

Sorry, you need to login or register to view additional sections of this Medicare policy.


All information on this web site is compiled directly from information obtained from the Center for Medicare and Medicaid Services (CMS) and from its Contractors.

CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this web site. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

No part of this web page or data displayed may be redistibuted or used without the express written consent of Wheaton Partners, LLC.

09/29/2023 05:52:11

CodeMap® is a Registered Trademark of Wheaton Partners, LLC.